Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Monte Rosa Therapeutics, Inc.

Market Cap 1.75B 1.54B 1.42B 1.33B 2.48B 166B 2.53B 17.01B 6.58B 81.32B 6.57B 6.43B 283B P/E 2026 *
-12.5x
P/E 2027 * -11.3x
Enterprise Value 1.75B 1.54B 1.42B 1.33B 2.48B 166B 2.53B 17.01B 6.58B 81.32B 6.57B 6.43B 283B EV / Sales 2026 *
39.3x
EV / Sales 2027 * 30.1x
Free-Float
99.42%
Yield 2026 *
-
Yield 2027 * -
05-07 Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-07 Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M MT
04-20 Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2026 on the Potential of its Cyclin E1-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors CI
03-17 Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
03-17 Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of US Federal Reserve Meeting MT
03-17 Monte Rosa Therapeutics, Inc. Announces Executive Changes CI
03-17 Monte Rosa Therapeutics Swings to Net Loss in Q4, Collaboration Revenue Falls MT
03-17 Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q4 Revenue $2.8M MT
03-16 Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer CI
03-16 Monte Rosa Therapeutics Signs Supply Deal With Johnson & Johnson for Phase 2 Prostate Cancer Study MT
03-16 Monte Rosa Therapeutics announces clinical supply agreement to support phase 2 trial evaluating MRT-2359 in combination with apalutamide for the treatment of metastatic castration-resistant prostate cancer RE
03-02 Monte Rosa Therapeutics Insider Sold Shares Worth $464,886, According to a Recent SEC Filing MT
02-24 Monte Rosa Therapeutics, Inc. Presents Updated Clinical Data from Phase 1/2 Study of MRT-2359 in Combination with Enzalutamide in Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer Patients At Asco Genitourinary Cancers CI
1 day+10.93%
1 week+16.61%
Current month+5.07%
1 month+10.10%
3 months+37.79%
6 months+25.67%
Current year+32.08%
1 week 17.9
Extreme 17.905
20.99
1 month 16.11
Extreme 16.11
20.99
Current year 13.69
Extreme 13.69
25.77
1 year 4.12
Extreme 4.12
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
45.56
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 2019-12-31
Chief Tech/Sci/R&D Officer - 2026-03-16
Chief Operating Officer 54 2021-02-28
Director TitleAgeSince
Director/Board Member 55 2019-12-31
Director/Board Member 49 2020-03-31
Director/Board Member 57 2020-05-31
Date Insider Type Main position Quantity % Market Cap.
06-16Fiscal year

Chief Technology Officer

9,000 0.0107%
06-16Fiscal year

Chief Operating Officer

6,528 0.0077%
06-10Free

Chairman

25,800 0.0305%
Change 5-day change 1-year change 3-year change Capi.($)
+10.93%+16.61%+346.34%+204.56% 1.58B
+2.96%+4.21%-8.16%-2.76% 43.24B
+2.23%+8.26%+323.35%+564.22% 35.25B
+1.59%+4.63%+7.23%+54.02% 30.22B
+2.07%-4.40%+10.38%-19.99% 28.01B
-4.75%-8.02%+5.99%+12.28% 24.08B
+4.64%+3.20% - - 14.16B
+3.91%+2.57%+53.41%+111.95% 13.01B
+2.77%+4.02%+9.61%+15.31% 12.7B
+0.13%+3.97%+101.73%+91.70% 12.54B
Average +2.65%+2.57%+94.43%+114.59% 21.48B
Weighted average by Cap. +1.72%+1.32%+71.47%+120.94%

Financials

2026 *2027 *
Net sales 44.48M 39.07M 36M 33.7M 63.15M 4.21B 64.21M 432M 167M 2.07B 167M 163M 7.19B 58.17M 51.1M 47.09M 44.08M 82.59M 5.51B 83.98M 565M 219M 2.7B 218M 214M 9.4B
Net income -167M -147M -135M -127M -238M -15.85B -242M -1.63B -629M -7.78B -628M -615M -27.03B -193M -170M -157M -147M -275M -18.33B -279M -1.88B -728M -8.99B -726M -711M -31.26B
Net Debt - -
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
187
Date Price Change Volume
26-06-23 US$20.71 +10.93% 1,752,735
26-06-22 US$18.67 +1.97% 1,790,465
26-06-18 US$18.31 -0.54% 2,507,724
26-06-17 US$18.41 +3.66% 1,184,533
26-06-16 US$17.76 -1.99% 795,061
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
20.71USD
Average target price
32.33USD
Spread / Average Target
+56.12%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLUE Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!